Caladrius Biosciences (NASDAQ:CLBS) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.20, Fidelity Earnings reports.
Caladrius Biosciences stock traded down $0.68 during midday trading on Friday, hitting $4.53. 21,628 shares of the stock were exchanged, compared to its average volume of 36,147. The stock has a market cap of $47.56 million, a PE ratio of -2.54 and a beta of 1.22. Caladrius Biosciences has a 52-week low of $2.91 and a 52-week high of $11.65.
Several research firms recently weighed in on CLBS. Chardan Capital restated a “buy” rating on shares of Caladrius Biosciences in a report on Wednesday, August 29th. Zacks Investment Research upgraded shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a report on Wednesday, September 12th. Finally, HC Wainwright boosted their price target on shares of Caladrius Biosciences to $15.00 and gave the stock a “buy” rating in a report on Monday, September 10th.
COPYRIGHT VIOLATION NOTICE: This news story was published by BBNS and is the property of of BBNS. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://baseballnewssource.com/2018/11/10/caladrius-biosciences-clbs-issues-quarterly-earnings-results-beats-estimates-by-0-20-eps/2973040.html.
Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.
Recommended Story: What is the Rule of 72?
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.